A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Brief summary (registry, in English)

The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emnergize

What you commit to

• Study type: Interventional · Phase 3
• Planned participants: 160
• From 16 Sept 2025 to the primary completion date, 7 Oct 2027
• 98 sites in 27 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (98)

Sites in registry order. Pick your city on the disease page to sort them by distance.